Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs

Nucleoside-modified messenger RNA (mRNA)-lipid nanoparticles (LNPs) are the basis for the first two EUA (Emergency Use Authorization) COVID-19 vaccines. The use of nucleoside-modified mRNA as a pharmacological agent opens immense opportunities for therapeutic, prophylactic and diagnostic molecular i...

Descripción completa

Detalles Bibliográficos
Autores principales: Tombácz, István, Laczkó, Dorottya, Shahnawaz, Hamna, Muramatsu, Hiromi, Natesan, Ambika, Yadegari, Amir, Papp, Tyler E., Alameh, Mohamad-Gabriel, Shuvaev, Vladimir, Mui, Barbara L., Tam, Ying K., Muzykantov, Vladimir, Pardi, Norbert, Weissman, Drew, Parhiz, Hamideh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571164/
https://www.ncbi.nlm.nih.gov/pubmed/34091054
http://dx.doi.org/10.1016/j.ymthe.2021.06.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571164/
https://www.ncbi.nlm.nih.gov/pubmed/34091054
http://dx.doi.org/10.1016/j.ymthe.2021.06.004

Ejemplares similares